Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares MSCI United Kingdom (FTSE) — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while iShares MSCI United Kingdom (FTSE) trades at $48.28. Which is the better fit depends on your goals.
| BIO | EWU | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $356.25 | $48.68 |
52-Week Low | $241.71 | $40.90 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EWU, the iShares MSCI United Kingdom ETF, trades at $48.64, up 0.7% with strong bullish technical signals from moving averages. The ETF shows mixed institutional activity with recent purchases by Balefire LLC and Fifth Third Bancorp offset by Bank of America trimming its position. UK market sentiment remains influenced by Middle East tensions, oil price volatility, and new political leadership under Prime Minister Andy Burnham.
The ETF's outlook balances UK economic resilience against geopolitical risks. Investment opportunity lies in exposure to FTSE 100 companies amid potential economic stabilization, while risks include ongoing Middle East tensions affecting energy markets and uncertainty around new UK fiscal policies under the Burnham administration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
